2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha has been researched along with beta-Thalassemia in 1 studies
*beta-Thalassemia: A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abramov, A; De Raucourt, E; Durst, R; Eldor, A; Gillis, S; Godefray, YC; Goldfarb, A; Guillin, MC; Hy-Am, E; MacLouf, J; Rachmilewitz, EA | 1 |
1 other study(ies) available for 2,3-dinor-6,15-diketo-13,14-dihydroprostaglandin f1alpha and beta-Thalassemia
| Article | Year |
|---|---|
A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Coagulation Factors; Child; Child, Preschool; Complement Inactivator Proteins; Glycoproteins; Humans; Mutation; Plasminogen; Prostaglandins F, Synthetic; Protein C; Protein S; Receptors, Complement; Thrombophilia; Thromboxane B2 | 1999 |